OTCMKTS:INVVY

Indivior Competitors

$9.40
-0.54 (-5.43 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.40
Now: $9.40
$9.60
50-Day Range
$8.21
MA: $8.83
$9.94
52-Week Range
$2.80
Now: $9.40
$40.00
Volume667 shs
Average Volume9,268 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3

Competitors

Indivior (OTCMKTS:INVVY) Vs. BPMC, GLPG, SDGR, BHVN, SAGE, and HCM

Should you be buying INVVY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Indivior, including Blueprint Medicines (BPMC), Galapagos (GLPG), Schrödinger (SDGR), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), and Hutchison China MediTech (HCM).

Blueprint Medicines (NASDAQ:BPMC) and Indivior (OTCMKTS:INVVY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Volatility and Risk

Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Blueprint Medicines and Indivior, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
Indivior00303.00

Blueprint Medicines currently has a consensus price target of $112.40, suggesting a potential upside of 20.63%. Given Blueprint Medicines' higher probable upside, equities analysts clearly believe Blueprint Medicines is more favorable than Indivior.

Earnings & Valuation

This table compares Blueprint Medicines and Indivior's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million81.20$-347,690,000.00($7.27)-12.82
Indivior$785 million1.76$134 million$1.158.17

Indivior has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Blueprint Medicines and Indivior's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Indivior-31.93%-4.15%-0.26%

Summary

Blueprint Medicines beats Indivior on 9 of the 13 factors compared between the two stocks.

Indivior (OTCMKTS:INVVY) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Insider and Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Indivior has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Indivior and Galapagos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior$785 million1.76$134 million$1.158.17
Galapagos$1.00 billion5.40$167.83 million$5.4615.16

Galapagos has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Indivior and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Indivior-31.93%-4.15%-0.26%
Galapagos-70.67%-11.78%-5.58%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Indivior and Galapagos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indivior00303.00
Galapagos210602.22

Galapagos has a consensus target price of $143.7273, indicating a potential upside of 73.44%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Indivior.

Summary

Galapagos beats Indivior on 9 of the 14 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Indivior (OTCMKTS:INVVY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Indivior, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Indivior00303.00

Schrödinger presently has a consensus target price of $85.50, indicating a potential upside of 19.40%. Given Schrödinger's higher probable upside, analysts plainly believe Schrödinger is more favorable than Indivior.

Insider and Institutional Ownership

41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Schrödinger and Indivior's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Indivior-31.93%-4.15%-0.26%

Valuation and Earnings

This table compares Schrödinger and Indivior's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million58.60$-24,570,000.00N/AN/A
Indivior$785 million1.76$134 million$1.158.17

Indivior has higher revenue and earnings than Schrödinger.

Summary

Indivior beats Schrödinger on 5 of the 9 factors compared between the two stocks.

Indivior (OTCMKTS:INVVY) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Profitability

This table compares Indivior and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Indivior-31.93%-4.15%-0.26%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Analyst Recommendations

This is a summary of recent ratings for Indivior and Biohaven Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indivior00303.00
Biohaven Pharmaceutical021002.83

Biohaven Pharmaceutical has a consensus target price of $96.7273, suggesting a potential upside of 29.38%. Given Biohaven Pharmaceutical's higher possible upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Indivior.

Earnings & Valuation

This table compares Indivior and Biohaven Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior$785 million1.76$134 million$1.158.17
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.86

Indivior has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Indivior has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biohaven Pharmaceutical beats Indivior on 7 of the 13 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Indivior (OTCMKTS:INVVY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sage Therapeutics and Indivior, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Indivior00303.00

Sage Therapeutics currently has a consensus price target of $86.6875, suggesting a potential upside of 19.32%. Given Sage Therapeutics' higher probable upside, analysts clearly believe Sage Therapeutics is more favorable than Indivior.

Earnings & Valuation

This table compares Sage Therapeutics and Indivior's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million620.53$-680,240,000.00($13.38)-5.46
Indivior$785 million1.76$134 million$1.158.17

Indivior has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sage Therapeutics and Indivior's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Indivior-31.93%-4.15%-0.26%

Volatility & Risk

Sage Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

Indivior beats Sage Therapeutics on 7 of the 12 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Indivior (OTCMKTS:INVVY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Hutchison China MediTech and Indivior's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Indivior-31.93%-4.15%-0.26%

Volatility and Risk

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Hutchison China MediTech and Indivior's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.87$-106,020,000.00($0.80)-36.71
Indivior$785 million1.76$134 million$1.158.17

Indivior has higher revenue and earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Hutchison China MediTech and Indivior, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Indivior00303.00

Hutchison China MediTech presently has a consensus target price of $40.00, suggesting a potential upside of 36.38%. Given Hutchison China MediTech's higher probable upside, equities analysts clearly believe Hutchison China MediTech is more favorable than Indivior.

Summary

Hutchison China MediTech beats Indivior on 7 of the 12 factors compared between the two stocks.


Indivior Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.18-0.6%$5.37 billion$66.51 million17.19Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.77-3.8%$5.22 billion$1.00 billion-12.54Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.5$71.60-2.2%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.86-1.6%$4.57 billionN/A-6.10Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.02-0.6%$4.29 billion$6.87 million-7.06Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.37-1.3%$4.22 billion$204.89 million-36.71
I-Mab logo
IMAB
I-Mab
1.4$55.63-2.1%$4.09 billion$4.31 million-1.92
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.41-1.0%$4.03 billion$806.43 million-9.55Analyst Report
Hypera logo
HYPMY
Hypera
0.9$6.24-1.1%$3.97 billion$834.89 million14.51Upcoming Earnings
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.10-1.1%$3.89 billion$117.91 million-11.18
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.04-0.1%$3.70 billionN/A-6.20
LEGN
Legend Biotech
1.2$27.23-1.9%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.50-0.2%$3.52 billion$1.11 billion21.06News Coverage
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$72.29-1.0%$3.50 billionN/A-20.60
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$41.10-3.0%$3.50 billionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.48-3.4%$3.43 billion$114.62 million-7.85
Insmed logo
INSM
Insmed
1.2$33.41-3.3%$3.34 billion$136.47 million-12.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.20-1.9%$3.33 billion$339.08 million-12.33Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$45.81-1.1%$3.26 billion$306.98 million-6.55
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.00-1.9%$3.23 billion$26.52 million-8.02Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.39-1.1%$3.21 billion$1.17 billion-44.33Insider Selling
Analyst Revision
News Coverage
InnovAge logo
INNV
InnovAge
1.3$23.99-1.2%$3.20 billion$23.99 million-7.34
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.51-0.5%$3.16 billion$36.13 million-67.93
Arvinas logo
ARVN
Arvinas
1.5$65.06-4.8%$3.03 billion$42.98 million-25.41Upcoming Earnings
Analyst Report
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.70-0.9%$2.96 billion$80.43 million108.10
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.47-0.4%$2.92 billionN/A-53.97News Coverage
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.63-0.9%$2.91 billion$644.77 million-10.93
OPKO Health logo
OPK
OPKO Health
1.9$4.31-4.2%$2.77 billion$901.90 million-23.94
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.78-1.8%$2.75 billion$421.03 million22.46News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.75-0.3%$2.65 billion$25 million-9.15Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.79-1.1%$2.64 billion$306.49 million25.61
Organogenesis logo
ORGO
Organogenesis
1.0$21.09-2.8%$2.62 billion$260.98 million-351.50News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.75-1.1%$2.61 billionN/A-23.49
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.82-0.4%$2.59 billion$182.24 million-8.54Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.74-1.1%$2.57 billion$2.11 million-9.03Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.58-3.3%$2.47 billion$60,000.00-9.19Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$149.15-1.6%$2.44 billion$120.28 million-150.66Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$41.72-0.4%$2.41 billion$156.70 million-29.80
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.07-4.8%$2.32 billion$23.90 million-18.06Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.24-3.9%$2.26 billion$15 million-17.40
Cryoport logo
CYRX
Cryoport
1.7$51.79-4.2%$2.26 billion$33.94 million-89.29
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.64-1.1%$2.25 billion$963.01 million14.17
ALX Oncology logo
ALXO
ALX Oncology
1.9$56.53-3.7%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$52.71-2.9%$2.10 billionN/A0.00Analyst Report
CytoDyn logo
CYDY
CytoDyn
0.9$3.33-5.1%$2.05 billionN/A-10.09
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$130.26-3.0%$2.02 billionN/A-11.77News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.46-0.6%$2.02 billion$64.19 million-10.69Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.58-3.0%$1.98 billion$103.54 million-19.98
Amarin logo
AMRN
Amarin
1.6$5.05-2.0%$1.95 billion$429.76 million-100.98
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.39-2.2%$1.91 billion$410,000.00-5.95
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.